Pharma Focus Asia

Eisai Boosts Venture Investment Focus to Drive Drug Discovery Innovation and Foster Ecosystem Platform

Tuesday, June 04, 2024

Eisai Co., Ltd., headquartered in Tokyo and led by CEO Haruo Naito, has announced plans to reinforce and continue its venture investment business, which was initiated in 2019. The primary goal is to identify innovative technologies and services, provide support to venture businesses possessing such technologies, and establish partnerships to accelerate drug discovery innovation and ecosystem platform development.

The investment business focuses on ventures that align with Eisai’s mission of contributing to patient welfare, particularly those with advanced drug discovery platforms relevant to Eisai’s strategic focus areas of neurology, oncology, and global health. It also encompasses digital technologies and services that facilitate ecosystem creation and operation through collaboration with other industries. Since its launch in May 2019, the venture investment arm has invested in more than 30 companies across various fields, including biologics, nucleic acids therapeutics, gene therapy, AI, data management, smart devices, and digital therapeutics. These investments have not only influenced Eisai’s corporate strategy but have also fostered collaborations and synergies with existing business ventures. Additionally, profits have been realized through the divestment of certain investments.

To strengthen the venture investment program, Eisai plans to increase the annual investment limit from 3 billion to 4 billion yen. Furthermore, it aims to enhance strategic returns by expanding collaboration opportunities across the entire organization to engage in a broader range of partnerships. Eisai also intends to invest in technologies and services in drug discovery and digital fields with potential innovations beyond its primary strategic domains and ecosystem-related fields.

Eisai is committed to leveraging the venture investment initiative to facilitate flexible collaboration with academia, drug discovery ventures, and IT enterprises to develop innovative medications targeting diseases with significant unmet medical needs. As an hhceco company, Eisai aims to address health concerns and reduce healthcare disparities by delivering solutions through ecosystem-driven collaboration with other industries.



Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024